Cancer of the anal region

Lisa Licitra, Silvia Spinazzé, Roberto Doci, T. R Jeffry Evans, Gunnar Tanum, Michel Ducreux

Research output: Contribution to journalArticle

Abstract

Cancer of the anal region represents 3-3.5% of all anorectal tumours. The peak incidence is between 58 and 64 years. Since 1960 an increased incidence among men younger than 45 years, and among women has been observed. The number of women diagnosed with anal canal cancer (7 per 1 000 000 person per years) is twice as much as that of men, while anal margins cancers are more frequent in men (4 per 1 000 000 person per years). Tumour extension determines the different treatment strategies, aiming at definite cure, with a conservative approach. Small tumours can be resected without mutilating surgery, while for larger tumours combination of chemotherapy and radiotherapy is the standard treatment, even though a combination of chemotherapy and radiotherapy has been recently introduced. Long-term quality of life (QOL) scores are acceptable, with the exception of patients who experience severe anal dysfunction.

Original languageEnglish
Pages (from-to)77-92
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume43
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Anus Neoplasms
Combination Drug Therapy
Neoplasms
Radiotherapy
Incidence
Anal Canal
Quality of Life
Therapeutics

Keywords

  • Anal region
  • Anorectal tumours
  • Cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Licitra, L., Spinazzé, S., Doci, R., Evans, T. R. J., Tanum, G., & Ducreux, M. (2002). Cancer of the anal region. Critical Reviews in Oncology/Hematology, 43(1), 77-92. https://doi.org/10.1016/S1040-8428(01)00193-7

Cancer of the anal region. / Licitra, Lisa; Spinazzé, Silvia; Doci, Roberto; Evans, T. R Jeffry; Tanum, Gunnar; Ducreux, Michel.

In: Critical Reviews in Oncology/Hematology, Vol. 43, No. 1, 2002, p. 77-92.

Research output: Contribution to journalArticle

Licitra, L, Spinazzé, S, Doci, R, Evans, TRJ, Tanum, G & Ducreux, M 2002, 'Cancer of the anal region', Critical Reviews in Oncology/Hematology, vol. 43, no. 1, pp. 77-92. https://doi.org/10.1016/S1040-8428(01)00193-7
Licitra, Lisa ; Spinazzé, Silvia ; Doci, Roberto ; Evans, T. R Jeffry ; Tanum, Gunnar ; Ducreux, Michel. / Cancer of the anal region. In: Critical Reviews in Oncology/Hematology. 2002 ; Vol. 43, No. 1. pp. 77-92.
@article{65f071c353a043ce8f830c67f8c5a49b,
title = "Cancer of the anal region",
abstract = "Cancer of the anal region represents 3-3.5{\%} of all anorectal tumours. The peak incidence is between 58 and 64 years. Since 1960 an increased incidence among men younger than 45 years, and among women has been observed. The number of women diagnosed with anal canal cancer (7 per 1 000 000 person per years) is twice as much as that of men, while anal margins cancers are more frequent in men (4 per 1 000 000 person per years). Tumour extension determines the different treatment strategies, aiming at definite cure, with a conservative approach. Small tumours can be resected without mutilating surgery, while for larger tumours combination of chemotherapy and radiotherapy is the standard treatment, even though a combination of chemotherapy and radiotherapy has been recently introduced. Long-term quality of life (QOL) scores are acceptable, with the exception of patients who experience severe anal dysfunction.",
keywords = "Anal region, Anorectal tumours, Cancer",
author = "Lisa Licitra and Silvia Spinazz{\'e} and Roberto Doci and Evans, {T. R Jeffry} and Gunnar Tanum and Michel Ducreux",
year = "2002",
doi = "10.1016/S1040-8428(01)00193-7",
language = "English",
volume = "43",
pages = "77--92",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Cancer of the anal region

AU - Licitra, Lisa

AU - Spinazzé, Silvia

AU - Doci, Roberto

AU - Evans, T. R Jeffry

AU - Tanum, Gunnar

AU - Ducreux, Michel

PY - 2002

Y1 - 2002

N2 - Cancer of the anal region represents 3-3.5% of all anorectal tumours. The peak incidence is between 58 and 64 years. Since 1960 an increased incidence among men younger than 45 years, and among women has been observed. The number of women diagnosed with anal canal cancer (7 per 1 000 000 person per years) is twice as much as that of men, while anal margins cancers are more frequent in men (4 per 1 000 000 person per years). Tumour extension determines the different treatment strategies, aiming at definite cure, with a conservative approach. Small tumours can be resected without mutilating surgery, while for larger tumours combination of chemotherapy and radiotherapy is the standard treatment, even though a combination of chemotherapy and radiotherapy has been recently introduced. Long-term quality of life (QOL) scores are acceptable, with the exception of patients who experience severe anal dysfunction.

AB - Cancer of the anal region represents 3-3.5% of all anorectal tumours. The peak incidence is between 58 and 64 years. Since 1960 an increased incidence among men younger than 45 years, and among women has been observed. The number of women diagnosed with anal canal cancer (7 per 1 000 000 person per years) is twice as much as that of men, while anal margins cancers are more frequent in men (4 per 1 000 000 person per years). Tumour extension determines the different treatment strategies, aiming at definite cure, with a conservative approach. Small tumours can be resected without mutilating surgery, while for larger tumours combination of chemotherapy and radiotherapy is the standard treatment, even though a combination of chemotherapy and radiotherapy has been recently introduced. Long-term quality of life (QOL) scores are acceptable, with the exception of patients who experience severe anal dysfunction.

KW - Anal region

KW - Anorectal tumours

KW - Cancer

UR - http://www.scopus.com/inward/record.url?scp=0036297472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036297472&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(01)00193-7

DO - 10.1016/S1040-8428(01)00193-7

M3 - Article

C2 - 12098609

AN - SCOPUS:0036297472

VL - 43

SP - 77

EP - 92

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -